

August 3, 2023

Elizabeth Mauro Director, Global Regulatory Science Pfizer Inc. 66 Hudson Boulevard East New York, NY 10001

Re: EUA220333/S003 Trade/Device Name: Lucira by Pfizer COVID-19 & Flu Test Dated: July 25, 2023 Received: July 25, 2023

Dear Elizabeth Mauro:

This is to notify you that your request to extend the product shelf-life claim for the Lucira by Pfizer COVID-19 & Flu Test from 12 months to 15 months when stored at 15-30°C, based on the results of your ongoing stability studies, is granted. In addition, we concur with the minor update to the Lucira by Pfizer COVID-19 & Flu Test box label. Upon review, we concur that the data and information submitted in EUA220333/S003 supports the requested updates for use with the Lucira by Pfizer COVID-19 & Flu Test.

By submitting this EUA revision for review by the Food and Drug Administration (FDA), you have complied with the Conditions of Authorization stated in the letter authorizing the emergency use of the Lucira by Pfizer COVID-19 & Flu Test reissued on June 15, 2023.

Sincerely yours,

Uwe Scherf, M.Sc., Ph.D. Director, Division of Microbiology Devices OHT7: Office of In Vitro Diagnostics Office of Product Evaluation and Quality Center for Devices and Radiological Health